日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral allosteric TYK2 inhibitor ESK-001 using a randomized, double-blind, placebo-controlled study design

采用随机、双盲、安慰剂对照研究设计,评估口服变构TYK2抑制剂ESK-001的安全性、耐受性、药代动力学和药效学。

Ucpinar, Sibel; Kwan, Joyce K; Hoffman, Joshua D; Tilley, Mera K; Douglas, Jeffrey A; Rubio, Roman G; Lu, Ruixiao; Nunn, Philip A; Langrish, Claire L

Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168)

评估 BTK 抑制剂 tolebrutinib (PRN2246, SAR442168) 的安全性、暴露量和药效学的 1 期临床试验

Owens, Timothy D; Smith, Patrick F; Redfern, Andrew; Xing, Yan; Shu, Jin; Karr, Dane E; Hartmann, Sonja; Francesco, Michelle R; Langrish, Claire L; Nunn, Philip A; Gourlay, Steven G

PRN473, an inhibitor of Bruton's tyrosine kinase, inhibits neutrophil recruitment via inhibition of macrophage antigen-1 signalling

PRN473是布鲁顿酪氨酸激酶的抑制剂,它通过抑制巨噬细胞抗原-1信号传导来抑制中性粒细胞的募集。

Herter, Jan M; Margraf, Andreas; Volmering, Stephanie; Correia, Benedito Eduardo; Bradshaw, J Michael; Bisconte, Angelina; Hill, Ronald J; Langrish, Claire L; Lowell, Clifford A; Zarbock, Alexander

Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis.

抗IL-23疗法抑制多种炎症通路,改善自身免疫性脑脊髓炎

Chen Yi, Langrish Claire L, McKenzie Brent, Joyce-Shaikh Barbara, Stumhofer Jason S, McClanahan Terrill, Blumenschein Wendy, Churakovsa Tatyana, Low Justin, Presta Leonard, Hunter Christopher A, Kastelein Robert A, Cua Daniel J

Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation

IL-23 和 IL-12 在关节自身免疫炎症中发挥着不同的促炎和抗炎作用

Murphy, Craig A; Langrish, Claire L; Chen, Yi; Blumenschein, Wendy; McClanahan, Terrill; Kastelein, Robert A; Sedgwick, Jonathon D; Cua, Daniel J